Septerna ends Phase 1 trial for hypoparathyroidism drug; Sanofi’s Merilog is approved

Plus, news about Basilea, TME Pharma and Perceive Biotherapeutics: Septerna stops work on Phase 1: The newly public biotech ended a healthy volunteer trial for SEP-786, its hypoparathyroidism ...